|RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)|
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
|Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance|
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3 (1), 1-8, 2012
|Focused specificity of intestinal TH 17 cells towards commensal bacterial antigens|
Y Yang, MB Torchinsky, M Gobert, H Xiong, M Xu, JL Linehan, F Alonzo, ...
Nature 510 (7503), 152-156, 2014
|Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway|
M Atefi, E von Euw, N Attar, C Ng, C Chu, D Guo, R Nazarian, ...
PloS one 6 (12), e28973, 2011
|BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors|
KB Dahlman, J Xia, K Hutchinson, C Ng, D Hucks, P Jia, M Atefi, Z Su, ...
Cancer discovery 2 (9), 791-797, 2012
|Polymer nanofiber‐embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells|
S Hou, L Zhao, Q Shen, J Yu, C Ng, X Kong, D Wu, M Song, X Shi, X Xu, ...
Angewandte Chemie 125 (12), 3463-3467, 2013
|Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma|
T Chodon, B Comin-Anduix, B Chmielowski, RC Koya, Z Wu, M Auerbach, ...
Clinical Cancer Research 20 (9), 2457-2465, 2014
|A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition|
H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ...
Cancer discovery 4 (1), 69-79, 2014
|Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy|
C Ma, AF Cheung, T Chodon, RC Koya, Z Wu, C Ng, E Avramis, ...
Cancer discovery 3 (4), 418-429, 2013
|Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations|
F Niehr, E von Euw, N Attar, D Guo, D Matsunaga, H Sazegar, C Ng, ...
Journal of translational medicine 9 (1), 1-13, 2011
|Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines|
E von Euw, M Atefi, N Attar, C Chu, S Zachariah, BL Burgess, S Mok, C Ng, ...
Molecular cancer 11 (1), 1-9, 2012
|Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma|
M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen, M Cerniglia, ...
Molecular cancer 14 (1), 1-12, 2015
|COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors|
H Escuin-Ordinas, M Atefi, Y Fu, A Cass, C Ng, RR Huang, S Yashar, ...
Molecular oncology 8 (2), 250-260, 2014
|Heritable gene regulation in the CD4: CD8 T cell lineage choice|
PDA Issuree, CP Ng, DR Littman
Frontiers in immunology 8, 291, 2017
|Niche-selective inhibition of pathogenic Th17 cells by targeting metabolic redundancy|
L Wu, KER Hollinshead, Y Hao, C Au, L Kroehling, C Ng, WY Lin, D Li, ...
Cell 182 (3), 641-654. e20, 2020
|The histone chaperone CAF-1 cooperates with the DNA methyltransferases to maintain Cd4 silencing in cytotoxic T cells|
C Ng, M Aichinger, T Nguyen, C Au, T Najar, L Wu, KR Mesa, W Liao, ...
Genes & development 33 (11-12), 669-683, 2019
|Anthrax toxin receptor 1/tumor endothelial marker 8: mutation of conserved inserted domain residues overrides cytosolic control of protective antigen binding|
JD Ramey, VA Villareal, C Ng, SC Ward, JP Xiong, RT Clubb, KA Bradley
Biochemistry 49 (34), 7403-7410, 2010
|CRAF R391W is a melanoma driver oncogene|
M Atefi, B Titz, J Tsoi, E Avramis, A Le, C Ng, A Lomova, A Lassen, ...
Scientific reports 6 (1), 1-11, 2016
|Tcf1 and Lef1 pack their own HDAC|
CP Ng, DR Littman
Nature immunology 17 (6), 615-616, 2016
|Melanomas with rare BRAF mutations and their responses to MAPK pathway blocking drugs.|
MS Atefi, CP Ng, DJ Wong, L Robert, H Escuin-Ordinas, A Lassen, ...
Cancer Research 73 (8 Supplement), 915-915, 2013